secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0000950170-25-047702
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen reports FY2024 net loss of $63.6M; secures $76.4M financing for ophthalmology pipeline
--------------------------------------------------------------------------------

- Net loss $63.6M for 2024 vs $43.0M in 2023; Q4 net loss $28.0M.
- Cash $34.6M at 12/31/2024; received $76.4M gross proceeds from March 2025 financing.
- Collaboration revenue $10.0M for 2024, driven by Boehringer milestone; zero in 2023.
- R&D expenses $21.1M, down from $27.2M in 2023 due to restructuring and program discontinuation.
- Company prioritizing ophthalmology programs; Boehringer advancing SZN-413 toward clinical testing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017025047702/0000950170-25-047702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017025047702/srzn-20250331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-047702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer